Table of Contents Author Guidelines Submit a Manuscript
Journal of Osteoporosis
Volume 2016, Article ID 8738959, 6 pages
http://dx.doi.org/10.1155/2016/8738959
Research Article

Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis

1Centro de Endocrinología, Rosario, Argentina
2Laboratorio de Biología Ósea, Facultad de Ciencias Médicas, Universidad Nacional de Rosario, Rosario, Argentina
3Consultorios de Investigación Clínica Endocrinológica y del Metabolismo Óseo (CICEMO), Buenos Aires, Argentina
4Mautalen Salud e Investigación, Buenos Aires, Argentina
5Laboratorio Osteoporosis y Enfermedades Metabólicas Óseas, INIGEM, UBA-CONICET, Hospital de Clínicas, Buenos Aires, Argentina
6Instituto de Diagnóstico e Investigaciones Metabólicas (IDIM), Cátedra de Osteología y Metabolismo Mineral, Universidad del Salvador, Buenos Aires, Argentina
7Consultorios Asociados de Endocrinología Dra. Laura Maffei, Buenos Aires, Argentina
8Centro de Endocrinología y Osteoporosis, La Plata, Argentina
9Hospital Milstein, Buenos Aires, Argentina
10Centro de Endocrinología y Osteopatías Médicas, Córdoba, Argentina
11Hospital Durand, Buenos Aires, Argentina
12Centro de Reumatología, Rosario, Argentina

Received 27 April 2016; Revised 24 June 2016; Accepted 12 July 2016

Academic Editor: Merry Jo Oursler

Copyright © 2016 A. Sánchez et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The aim of this study was to evaluate the effect of denosumab (Dmab) on bone mineral density (BMD) and bone turnover markers after 1 year of treatment. Additionally, the effect of Dmab in bisphosphonate-naïve patients (BP-naïve) compared to patients previously treated with bisphosphonates (BP-prior) was analyzed. This retrospective study included 425 postmenopausal women treated with Dmab for 1 year in clinical practice conditions in specialized centers from Argentina. Participants were also divided according to previous bisphosphonate treatment into BP-naïve and BP-prior. A control group of patients treated with BP not switched to Dmab matched by sex, age, and body mass index was used. Data are expressed as mean ± SEM. After 1 year of treatment with Dmab the bone formation markers total alkaline phosphatase and osteocalcin were significantly decreased (23.36% and 43.97%, resp.), as was the bone resorption marker s-CTX (69.61%). Significant increases in BMD were observed at the lumbar spine, femoral neck, and total hip without differences between BP-naïve and BP-prior. A better BMD response was found in BP-prior group compared with BP treated patients not switched to Dmab. Conclusion. Dmab treatment increased BMD and decreased bone turnover markers in the whole group, with similar response in BP-naïve and BP-prior patients. A better BMD response in BP-prior patients versus BP treated patients not switched to Dmab was observed.